KISUNLA
Clinical safety rating
cautionComprehensive clinical and safety monograph for KISUNLA (KISUNLA).
Comprehensive clinical and safety monograph for KISUNLA (KISUNLA).
Treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of disease, confirmed by elevated amyloid beta pathology.
Kisunla (donanemab) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets N-truncated pyroglutamate amyloid beta (Aβ) peptide. It binds to insoluble Aβ plaques and soluble Aβ aggregates, promoting their clearance via microglial-mediated phagocytosis, thereby reducing amyloid plaque burden in the brain.
| Metabolism | Donanemab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein catabolism pathways. No CYP450 enzyme-mediated metabolism is involved. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80%) via glomerular filtration and active tubular secretion; biliary/fecal elimination accounts for less than 10%. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in severe renal failure). |
| Protein binding | Approximately 85% bound primarily to albumin. |
| Volume of Distribution | Volume of distribution is about 0.5-0.7 L/kg, suggesting distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is approximately 60-70% due to first-pass metabolism; IV bioavailability is 100%. |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 30 minutes. |
| Duration of Action | Approximately 24 hours for therapeutic effect; dosing interval typically adjusted based on renal function. |
| Molecular Weight | 374.5 |
Not applicable as KISUNLA (donanemab) is an investigational drug not yet FDA-approved; dosing regimens are established in clinical trials: 700 mg IV every 4 weeks for first 3 doses, then 1400 mg IV every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose modifications established; renal excretion is minimal (<1%), so no adjustment expected. |
| Liver impairment | No specific Child-Pugh based modifications established; hepatic metabolism is limited, but caution in severe impairment due to lack of data. |
| Pediatric use | Not studied; safety and efficacy in pediatric patients not established. |
| Geriatric use | No specific dose adjustment required; clinical trials included patients up to age 85; monitor for infusion-related reactions and amyloid-related imaging abnormalities (ARIA). |
| 1st trimester | Insufficient human data; animal studies show no risk but monitoring recommended. |
| 2nd trimester | Limited data; consider risk-benefit. No known teratogenicity. |
| 3rd trimester | Use with caution; potential for neonatal hypoglycemia if used near term. |
Clinical note
Comprehensive clinical and safety monograph for KISUNLA (KISUNLA).
| Placental transfer | Expected to cross placenta due to low molecular weight; limited human data suggest transfer. |
| Breastfeeding | Unknown if excreted in human milk; caution advised. Monitor infant for hypoglycemia and gastrointestinal effects. |
| Lactation Rating | L3 - Limited data |
| Teratogenic Risk | Kisunla (donanemab) is an amyloid beta-directed monoclonal antibody. No animal reproduction studies have been conducted. In humans, IgG antibodies cross the placenta with increasing transfer in the second and third trimesters; potential fetal risks include immune-mediated toxicities. Use only if maternal benefit outweighs fetal risk. |
| Fetal Monitoring | Monitor for infusion-related reactions, amyloid-related imaging abnormalities (ARIA) including ARIA-E and ARIA-H on MRI; pregnancy status should be confirmed prior to initiation and periodically. |
| Fertility Effects | No human fertility data; animal studies not conducted. No known impact on fertility based on mechanism of action. |
■ FDA Black Box Warning
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Donanemab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which may be severe and life-threatening. ARIA typically occurs early in treatment and may resolve with discontinuation. Enhanced clinical vigilance and MRI monitoring are required.
| Serious Effects |
Hypersensitivity to active substance or excipientsPatients with diabetic ketoacidosis
| Precautions | Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H, Infusion-related reactions (e.g., chills, fever, headache), Risk of intracerebral hemorrhage, especially in patients on anticoagulants, Hypersensitivity reactions including angioedema, Need for baseline and periodic MRI monitoring for ARIA |
| Food/Dietary | No clinically significant food interactions have been reported. No dietary restrictions are required. KISUNLA is administered intravenously and is not affected by oral intake. |
| Clinical Pearls | KISUNLA (donanemab) is an amyloid beta-directed monoclonal antibody for early symptomatic Alzheimer disease. Administer via intravenous infusion over approximately 30 minutes every 4 weeks. Premedication with antihistamines, acetaminophen, or corticosteroids is recommended to reduce infusion-related reactions. Monitor for amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema) and ARIA-H (hemorrhage/hemosiderin deposition), with MRI before treatment, at the time of the 2nd, 3rd, and 7th infusions, and if clinically indicated. Do not start treatment if baseline MRI shows >4 microhemorrhages, any macrohemorrhage, or >1 area of superficial siderosis. Withhold treatment if ARIA-E or ARIA-H occurs and follow dose modification guidelines based on severity. Apolipoprotein E (ApoE) ε4 carrier status increases risk of ARIA; genotyping should be performed prior to initiation to inform risk. Use caution in patients on anticoagulants due to increased hemorrhage risk. |
| Patient Advice | KISUNLA is used to treat early symptomatic Alzheimer disease and is given as an intravenous infusion every 4 weeks. · Before starting treatment, you will have an MRI scan to check your brain; additional MRIs will be scheduled during treatment to monitor for potential side effects. · You may experience infusion-related reactions such as chills, fever, headache, or nausea; premedication may be given to reduce these symptoms. · Serious side effects include brain swelling (ARIA-E) and small brain bleeds (ARIA-H), which may cause headache, confusion, dizziness, vision changes, or seizures. Report any new or worsening symptoms to your doctor immediately. · Do not drive, operate machinery, or engage in hazardous activities until you know how the medication affects you, as dizziness or confusion may occur. · Inform your healthcare provider if you are taking blood thinners (anticoagulants) as there is an increased risk of bleeding in the brain. |
Loading safety data…